Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:13 PM ET 8-K
Financial Results Allogene Therapeutics, Inc. ALLO

Allogene Therapeutics Financial Results

Allogene Therapeutics reported financial results for the third quarter of 2026, ending the period with $388.9 million in cash and investments. The company highlighted enrollment momentum in its pivotal Phase 2 ALPHA3 trial for cema-cel in LBCL and upcoming data presentations for its autoimmune candidate ALLO-329.

Term
Q3 2026

“We believe 2027 will be an important year for cema-cel and the field, with upcoming ALPHA3 data expected to provide important insights into the potential for CAR T to be integrated into existing practice patterns, earlier in the course of a patient’s disease and closer to where they receive care.”

Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer

“Both programs reflect our conviction that the future of CAR T will be shaped not only by what these therapies can do, but by how we make them more accessible and practical for patients.”

Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer
4:13 PM ET 8-K
Financial Results CareTrust REIT, Inc. CTRE

CareTrust REIT Financial Results

CareTrust REIT reported Q3 2026 financial results with Normalized FFO per share increasing 20% year-over-year to $0.54. The company highlighted record year-to-date investment activity of $2.9 billion, including the initial closing of a major £1.1 billion U.K. care home portfolio acquisition from LNT Care Developments.

“Normalized FFO per share increased 20% year-over-year and the team set another record of approximately $2.9 billion invested across skilled nursing, SHOP, and UK care homes, all while positioning the balance sheet for continued strong growth in the near to mid-term.”

Dave Sedgwick, Chief Executive Officer

“The CareTrust flywheel continues to accretively deliver year-over-year growth of our asset base and FFO. The relationship with LNT is a multiplier to our SHOP and UK care home growth engines. We've never been more excited for the runway ahead.”

Dave Sedgwick, Chief Executive Officer
4:13 PM ET 10-Q
Financial Results TransMedics Group, Inc. TMDX

TransMedics Group Q3 2026 Results: Net Income $17.1M, Down 29.8% YoY

TransMedics Group reported total revenue of $203.0 million for the third quarter of 2026, a 41% increase year-over-year, driven by growth in both product and service revenue. Net income for the quarter was $17.1 million, down from $24.3 million in the prior year period, primarily due to increased operating expenses in research, development, and clinical trials.

Key figure
Net income $17.1M · -29.8% YoY
4:13 PM ET 8-K
Financial Results Synaptics Inc SYNA

Synaptics Financial Results

Synaptics reported Q1 fiscal 2027 revenue of $294.0 million, a 1% increase year-over-year, despite supply constraints and smartphone market softness. The company reported a GAAP net loss of $17.7 million but achieved non-GAAP net income of $51.5 million. Due to its pending all-cash acquisition by onsemi, Synaptics did not provide forward-looking guidance.

Term
Q1 2027

“Synaptics delivered another quarter of strong design activity and customer engagement in Edge and Physical AI. We are continuing to see broader opportunities for our tactile sensing controllers and video interface products in robotics, and these new customers are showing growing interest in our processor and wireless technologies leveraging Edge AI development platforms.”

Rahul Patel, Synaptics' President and Chief Executive Officer

“Fiscal first quarter revenue was affected by supply constraints and memory-related demand dynamics across multiple markets, with smartphone softness impacting our touch and wireless products. During the quarter, we entered into a licensing agreement for our automotive LCD TDDI technology, consistent with our strategy to focus on higher-value areas and grow in Physical AI and Edge AI.”

Rahul Patel, Synaptics' President and Chief Executive Officer
4:13 PM ET 10-Q
Financial Results Vera Therapeutics, Inc. VERA

Vera Therapeutics Q3 2026 Results: Net Loss of $93.7M, Loss Widens

Vera Therapeutics received accelerated FDA approval for its lead product, TRUTAKNA, in July 2026 and began recording limited product revenue. The company remains in a net loss position as it scales commercialization efforts and continues clinical development for other indications and product candidates.

Key figure
Net loss $93.7M
4:13 PM ET 8-K
Financial Results Outfront Media Inc. OUT

Outfront Media Financial Results

OUTFRONT Media reported third quarter 2026 revenues of $511.1 million, a 9.3% increase year-over-year driven by strength in billboard and transit advertising. The company also declared a quarterly cash dividend of $0.33 per share and indicated expectations for double-digit revenue growth for the full year 2026.

Term
Q3 2026

“Our third quarter revenues grew over 9% given broad strength across all aspects of our business, and resulted in healthy Adjusted OIBDA and AFFO growth. We currently expect 2026 will be a double-digit revenue growth year, reflecting our focused execution and IRL’s re-emergence as an integral part of advertisers’ marketing campaigns.”

Nick Brien, Chief Executive Officer of OUTFRONT Media
4:13 PM ET 8-K
Financial Results Fulgent Genetics, Inc. FLGT

Fulgent Genetics Financial Results

Fulgent Genetics reported Q3 2026 revenue of $90.4 million, representing 8% year-over-year growth. The company reported a GAAP loss of $13.2 million and maintained its full-year 2026 revenue guidance of $330 million to $340 million. Management highlighted momentum in their therapeutics pipeline and the integration of AI into laboratory services workflows.

Term
Q3 2026

“We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”

Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer

“We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”

Paul Kim, Chief Financial Officer
4:13 PM ET 8-K
Financial Results JFrog Ltd FROG

JFrog Financial Results

JFrog Ltd. reported third quarter 2026 revenue of $179.2 million, a 31% increase year-over-year, driven by 60% growth in cloud revenue. The company achieved a non-GAAP operating margin of 22.7% and expanded its high-value customer base, with those generating over $1 million in ARR growing 58% to 112 customers.

Term
Q3 2026

“AI agents are writing code faster than any developer can review it. Every output becomes an artifact that must be stored, secured, and governed. Speed without trust can’t scale. Enterprises are standardizing on the JFrog Platform as a system of record for their software supply chain; a control plane that gives users both, under one Platform. Our Q3 performance reflects this momentum.”

Shlomi Ben Haim, CEO and Co-founder of JFrog
4:13 PM ET Form 4
Insider Buying Sanfilippo John B & Son Inc JBSS

Sanfilippo John B & Son Sr. VP, Corporate Controller Michael J. Finn Buys $11.2K of Stock

Michael J. Finn, Sr. VP, Corporate Controller, bought 200 shares of Sanfilippo John B & Son Inc at $56.08 a share, worth $11.2K in total on Nov 5, 2026. Shares held after the trade: 7,276 (+2.8%).

Value
$11.2K
Shares
200
Price
$56.08
Role
Sr. VP, Corporate Controller
Holding change
+2.8%
Trade date
Nov 5, 2026
4:13 PM ET 8-K
Financial Results Guardant Health, Inc. GH

Guardant Health Financial Results

Guardant Health reported Q3 2026 revenue of $361.0 million, a 36% increase year-over-year, driven by strong performance in its Oncology and Screening segments. The company raised its full-year 2026 revenue guidance to a range of $1.36 billion to $1.37 billion and highlighted the FDA approval of Guardant360 CDx as a companion diagnostic for breast cancer.

Term
Q3 2026

“Revenue grew 36% year over year as we continued to execute across Oncology, Screening, and Biopharma. Oncology volume grew 58% with broad contributions across our portfolio. The FDA approval of Guardant360 CDx for longitudinal ESR1 testing is a major advance for breast cancer patients, ushering in a new paradigm of cancer treatment. It reinforces the role of Guardant360 in enabling earlier therapy decisions and strengthens our leadership across the cancer care continuum.”

Helmy Eltoukhy, co-founder and co-CEO

“Shield continued to build momentum in the third quarter, with volume more than tripling year over year to 83,000 tests. Commercial coverage continues to expand, with recent policy updates extending Shield coverage to approximately 100 million lives. With our lower COGS, higher-throughput workflow now fully implemented, we have a strong operational foundation to meet future Shield demand. Together, these advances expand access to Shield and move us closer to making blood-based cancer screening a routine part of preventive care.”

AmirAli Talasaz, co-founder and co-CEO
4:13 PM ET 8-K
Financial Results Halozyme Therapeutics, Inc. HALO

Halozyme Therapeutics Financial Results

Halozyme Therapeutics reported record Q3 2026 financial results with total revenue increasing 39% year-over-year to $493 million, driven by a 44% surge in royalty revenue. Based on strong performance, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and non-GAAP EPS while highlighting a legal victory in the Netherlands protecting its intellectual property against Merck.

Term
Q3 2026

“Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels.”

Dr. Helen Torley, President and Chief Executive Officer

“Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026.”

Darren Snellgrove, Executive Vice President and Chief Financial Officer
4:13 PM ET 10-Q
Financial Results Fulgent Genetics, Inc. FLGT

Fulgent Genetics Q3 2026 Results: Net Loss of $13.2M, Loss Widens

Fulgent Genetics reported a net loss of $13.2 million for Q3 2026 on revenue of $90.4 million, compared to a net loss of $6.6 million on $84.1 million in revenue for the same period in 2025. The company's cash and marketable securities position decreased significantly from $636.0 million at year-end 2025 to $652.3 million as of September 30, 2026, impacted by $64.6 million in common stock repurchases during the first nine months of the year.

Key figure
Net loss $13.2M
4:13 PM ET 10-Q
Financial Results Bentley Systems Inc BSY

Bentley Systems Q3 2026 Results: Net Income $89.9M, Up 56.8% YoY

Bentley Systems reported total revenues of $421.5 million for the third quarter of 2026, a 12.2% increase compared to the same period in 2025, driven primarily by subscription growth. Net income attributable to the company rose significantly to $89.9 million, up from $57.4 million in the prior year, reflecting improved operating margins and higher income from operations.

Key figure
Net income $89.9M · +56.8% YoY
4:13 PM ET 10-Q
Financial Results BRC Group Holdings, Inc. RILY

BRC Group Holdings Q3 2026 Results: Net Loss of $241M

For the nine months ended September 30, 2026, BRC Group Holdings, Inc. reported total revenues of $624.2 million and a net loss of $3.9 million, a significant decline from the $220.0 million net income in the prior year period. The company's balance sheet shows a total deficit of $44.6 million, though this improved from a $120.3 million deficit at the end of 2025.

Key figure
Net loss $241M
4:13 PM ET 8-K
Leadership Change Inogen Inc INGN

Inogen Leadership Change

Inogen appointed current COO Andy Reding as President and CEO and a member of the Board of Directors, effective October 30, 2026. He succeeds Kevin R.M. Smith, whose role as an officer and employee ended on the same date. The transition occurs as the company focuses on a more streamlined commercial model following the divestiture of its U.S. rental business.

4:13 PM ET 8-K
Financial Results indie Semiconductor, Inc. INDI

indie Semiconductor Financial Results

indie Semiconductor reported Q3 2026 revenue of $70.2 million, representing 31% year-over-year growth and exceeding the midpoint of its previous outlook. The company narrowed its non-GAAP operating loss to $7.2 million and highlighted a major radar chipset design win with a top-three North American OEM.

Term
Q3 2026

“We reported strong third quarter results, with revenue up 31 percent year-over-year, ahead of our outlook, and our non-GAAP operating loss narrowed by more than a third. Our radar chipset, in high-volume production, has been selected by one of the top three North American OEMs, our sensing and perception portfolio is expanding rapidly into Physical AI, and with our fourth quarter outlook implying approximately 33 percent year-over-year growth, indie is very well positioned for the future.”

Donald McClymont, indie’s co-founder and chief executive officer
4:13 PM ET 10-Q
Financial Results Mustang Bio, Inc. MBIO

Mustang Bio Q3 2026 Results: Net Loss of $964K, Loss Widens

Mustang Bio, Inc. reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to $1.4 million in the prior year period. As of September 30, 2026, the company maintained $14.3 million in cash and cash equivalents and an accumulated deficit of $401.6 million, noting that additional capital will be required to fund future operations.

Key figure
Net loss $964K
4:13 PM ET 8-K
Financial Results FIGS, Inc. FIGS

FIGS Financial Results

FIGS, Inc. reported third quarter 2026 financial results with net revenues increasing 25.7% year-over-year to $190.7 million, driven by strong growth in both scrubwear and international markets. The company achieved a net income of $19.3 million and raised its full-year 2026 revenue growth outlook to approximately 23.5%.

Term
Q3 2026

“Our momentum continued in Q3, which marked our fourth straight quarter of greater than 25% net revenues growth, powered by consistent strength across our categories, channels and geographies. This inflection in our business reflects the combined power of great product, marketing campaigns that resonate deeply, a passionate community and strong industry fundamentals.”

Trina Spear, Chief Executive Officer and Co-Founder

“We performed at a high level in Q3, delivering better-than-expected overall results. Net revenues grew 26%, highlighted by accelerations in active customer growth to 14.3%, average order value growth to 10.5%, and net revenues per active customer, which grew to a record $236.”

Sarah Oughtred, Chief Financial Officer
4:13 PM ET 8-K
Financial Results MasterBrand, Inc. MBC

MasterBrand Financial Results

HA Sustainable Infrastructure Capital (HASI) reported third quarter 2026 financial results with GAAP EPS of $1.04 and Adjusted EPS of $0.82. The company's managed assets grew 27% year-over-year to $19.0 billion, and management reaffirmed its 2028 guidance for Adjusted EPS and ROE.

Term
Q3 2026

“Our team continues to execute on our business plan by adding new clients and deepening our relationships with existing ones, further diversifying into new asset classes, and optimizing our capital platform. These factors have translated into superb financial results through the first three quarters of 2026 with our Managed Assets increasing nearly $3 billion to $19 billion, Adjusted Recurring Net Investment Income growing 23% and Adjusted EPS by 15% year-to-date, and our Adjusted ROE rising to 15.6%.”

Jeffrey A. Lipson, President and Chief Executive Officer

“As much of the global economy has been adjusting to the increase in interest rates over the last few months, HASI continues to demonstrate the benefits of our business model in mitigating the impacts of a higher interest rate environment. Our new asset yields have increased to more than 11% year-to-date and we have continued to maintain our net investment margins. In combination with our growing base of management fees, we are generating greater profitability that is increasingly resilient to changes in the interest rate environment.”

Chuck Melko, Chief Financial Officer
4:13 PM ET 10-Q
Financial Results San Diego Gas & Electric Co SRE

San Diego Gas & Electric Q3 2026 Results: Net Income $883M, Up 829.5% YoY

For the nine months ended September 30, 2026, Sempra reported net income of $3,206 million, a significant increase from $1,588 million in 2025, driven by higher equity earnings and a gain on sales. Total revenues remained relatively stable at $9,843 million, while the company continued heavy capital investment with $7,327 million in property, plant, and equipment expenditures.

Key figure
Net income $883M · +829.5% YoY
4:13 PM ET 8-K
Financial Results Teradata Corp TDC

Teradata Financial Results

Teradata reported third quarter 2026 financial results with total revenue of $399 million and non-GAAP diluted EPS of $0.70. The company saw public cloud ARR growth of 11% year-over-year and narrowed its full-year revenue outlook to the high end of previous ranges while increasing its EPS guidance.

Term
Q3 2026

“In Q3, Teradata marked another quarter of progress against the goals we set at the start of the year, driving total ARR growth, improving profitability and delivering strong free cash flow. The increased pace of new product innovation and new AI service capabilities is driving positive interest from customers.”

Steve McMillan, president and CEO, Teradata
4:13 PM ET 10-Q
Financial Results Southern California Gas Co SRE

Southern California Gas Q3 2026 Results: Net Income $883M, Up 829.5% YoY

For the nine months ended September 30, 2026, Sempra reported total revenues of $9,843 million and net income of $3,206 million, a significant increase from $1,588 million in the prior year. The results were impacted by a $214 million gain on sales and higher equity earnings, partially offset by $205 million in regulatory disallowances.

Key figure
Net income $883M · +829.5% YoY
4:13 PM ET 10-Q
Financial Results Sempra SRE

Sempra Q3 2026 Results: Net Income $883M, Up 829.5% YoY

Sempra reported a significant increase in net income for the nine months ended September 30, 2026, reaching $3,206 million compared to $1,588 million in the prior year. This growth was driven by higher equity earnings and a gain on sales, despite a $205 million regulatory disallowance and increased interest expenses.

Key figure
Net income $883M · +829.5% YoY
4:12 PM ET 8-K
Financial Results Simon Property Group Inc. SPG

Simon Property Group Financial Results

Simon Property Group reported Q3 2026 Real Estate FFO of $1.277 billion, or $3.37 per diluted share, representing a 4.7% increase year-over-year. The company increased its full-year 2026 Real Estate FFO guidance and raised its quarterly dividend following strong leasing momentum and shopper traffic growth.

Term
Q3 2026

“We delivered another quarter of excellent financial and operational results. Leasing momentum continued, rents and occupancy increased and shopper traffic growth accelerated for the third consecutive quarter, driving robust retailer sales growth across our portfolio. Today, we are once again increasing our full-year 2026 Real Estate FFO per share guidance and raising our quarterly dividend.”

Eli Simon, Chief Executive Officer, President and Chief Operating Officer
4:12 PM ET Form 4
Insider Selling Figma, Inc. FIG

Figma General Counsel and Secretary Brendan Mulligan Sells $247K of Stock

Brendan Mulligan, General Counsel and Secretary, sold 11,599 shares of Figma, Inc. at $21.30 a share, worth $247K in total on Nov 3, 2026. Shares held after the trade: 555,656 (-2.0%).

Value
$247K
Shares
11,599
Price
$21.30
Role
General Counsel and Secretary
Holding change
-2.0%
Trade date
Nov 3, 2026
4:12 PM ET 8-K
M&A Deal Willdan Group, Inc. WLDN

Willdan Group Signs $285M M&A Deal with Mantis Intermediate Holdings, LLC

Willdan Group completed its acquisition of Mantis Innovation for approximately $285 million in cash. The transaction was funded through $250 million in new term loan borrowings and $35 million from an existing revolving credit facility.

Value
$285M
Counterparty
Mantis Intermediate Holdings, LLC
4:12 PM ET 10-Q
Financial Results Castle Biosciences Inc CSTL ▶ Call

Castle Biosciences Q3 2026 Results: Net Loss of $4.1M, Loss Widens

Castle Biosciences reported net revenues of $102.9 million for the third quarter of 2026, up from $83.0 million in 2025. Despite the revenue growth, the company realized a net loss of $4.1 million for the quarter, primarily driven by increased operating expenses in selling, general, and administrative functions.

Key figure
Net loss $4.1M
4:12 PM ET 8-K
Financial Results Akamai Technologies Inc AKAM

Akamai Technologies Financial Results

Akamai Technologies reported Q3 2026 revenue of $1.12 billion, up 6% year-over-year, driven by 34% growth in Cloud Infrastructure Services. The company issued bullish long-term guidance, projecting revenue growth to accelerate to 17-22% in 2027 and total revenue to exceed $7.0 billion in 2028.

Term
Q3 2026

“Akamai delivered solid third quarter results, driven by continued momentum across security and Cloud Infrastructure Services (CIS). We are especially excited by the exceptional progress in Cloud Infrastructure Services, with more than $14 billion worth of multi-year commitments signed so far this year.”

Dr. Tom Leighton, Akamai's Chief Executive Officer

“Given our CIS momentum, track record of execution and continued strong pipeline, we expect Akamai's overall revenue growth to accelerate to 17% to 22% year-over-year when adjusted for foreign exchange* in 2027. We expect further acceleration in 2028 with total revenue projected to exceed $7.0 billion.”

Dr. Tom Leighton, Akamai's Chief Executive Officer
4:12 PM ET 8-K
Financial Results Definitive Healthcare Corp. DH

Definitive Healthcare Financial Results

Definitive Healthcare reported Q3 2026 revenue of $54.7 million, a 9% decrease year-over-year, while narrowing its net loss to $5.4 million. The company noted it will not provide forward guidance or host an earnings call due to a pending non-binding acquisition proposal from Advent International.

Term
Q3 2026

“Since joining Definitive, I’ve been focused on listening to our customers and our employees. What I’ve heard confirms my belief in the strength of our position in the market, and it has also shown me where we can execute better. This quarter’s results demonstrate the underlying health of the business and a solid foundation to build upon.”

Clay Ritchey, CEO of Definitive Healthcare

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.